Target intelligence / Profile preview

Dopamine- and cyclic AMP-regulated phosphoprotein 32 kDa (DARPP-32) (DARPP-32)

Target
DARPP-32
Molecular classification
Phosphoprotein, Phosphatase inhibitor protein, Kinase inhibitor protein, Signal transduction molecule, Cytosolic protein
01

Overview

DARPP-32 is a 32 kDa phosphoprotein highly enriched in medium spiny neurons of the striatum, where it acts as a key integrator of dopamine and glutamate signaling. Its phosphorylation state, regulated by multiple kinases and phosphatases, determines whether it inhibits PP1 (promoting protein phosphorylation) or PKA (reducing cAMP signaling). This dual regulatory capacity allows DARPP-32 to function as a molecular switchboard, modulating the response of neurons to neurotransmitters, drugs, and environmental stimuli. DARPP-32 is essential for normal striatal function, reward processing, and behavioral responses to both natural and pharmacological stimuli. Abnormalities in DARPP-32 expression or phosphorylation are linked to neurological and psychiatric disorders, as well as certain cancers. Its complex regulation and central role in multiple signaling pathways make it a challenging but important potential therapeutic target.

Other names
Protein phosphatase 1 regulatory subunit 1BPpp1r1bPhosphoprotein phosphatase-1 regulatory subunit 1BDopamine and cAMP-regulated phosphoprotein of 32 kDa
02

Mechanism of action

DARPP-32 is a bifunctional phosphoprotein that, when phosphorylated at threonine-34 (by cAMP-dependent protein kinase, PKA), acts as a potent inhibitor of protein phosphatase 1 (PP1); when phosphorylated at threonine-75 (by cyclin-dependent kinase 5, CDK5), it inhibits PKA. Its activity is modulated by dopamine via D1 receptors (increases Thr34 phosphorylation), glutamate (can both increase and decrease Thr34 phosphorylation via different pathways), and calcium (modulates dephosphorylation via calcineurin/PP2B and PP2A). Additional phosphorylation at serine-137 (by casein kinase 1, CK1) and serine-102 (by casein kinase 2, CK2) further fine-tunes its activity, creating a signaling hub that integrates multiple neurotransmitter inputs.

03

Biological functions

Signal transductionIntegration of dopamine and glutamate signalingNeuronal excitability modulationRegulation of protein phosphorylation cascadesNeurotransmissionSynaptic plasticityReward processingBehavioral response to natural and drug-related stimuli
04

Disease associations

Psychiatric disorders (e.g., schizophrenia, addiction)Neurological disorders (e.g., Parkinson’s disease, dyskinesia)StrokeCancer (e.g., ovarian cancer, breast cancer, possibly others)
05

Safety considerations

Indirect modulation by drugs of abuse and psychotropic medications can lead to addiction or dyskinesia.Aberrant DARPP-32 signaling has been implicated in both psychiatric and neurological side effects.Targeting DARPP-32 directly for therapeutic purposes is challenging due to its central integration role and potential for broad systemic effects.
06

Interacting drugs

Cocaine

4 more in the full profile.

07

Biomarkers

Protein level of DARPP-32Phosphorylation at Thr34, Thr75, Ser137, Ser102 (indicative of specific signaling states in neurons or tumors)Nuclear vs. cytoplasmic localization (cancer context)

Beyond the preview

Go deeper on Dopamine- and cyclic AMP-regulated phosphoprotein 32 kDa (DARPP-32) (DARPP-32).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dopamine- and cyclic AMP-regulated phosphoprotein 32 kDa (DARPP-32) (DARPP-32).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call